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Abstract
Virus-encoded microRNAs (miRNAs) have been shown to regulate a variety of biological processes involved in viral infection
and viral-associated pathogenesis. Epstein-Barr virus (EBV) is a herpesvirus implicated in nasopharyngeal carcinoma (NPC)
and other human malignancies. EBV-encoded miRNAs were among the first group of viral miRNAs identified. To understand
the roles of EBV miRNAs in the pathogenesis of NPC, we utilized deep sequencing technology to characterize the EBV
miRNA transcriptome in clinical NPC tissues. We obtained more than 110,000 sequence reads in NPC samples and identified
44 EBV BART miRNAs, including four new mature miRNAs derived from previously identified BART miRNA precursor hairpins.
Further analysis revealed extensive sequence variations (isomiRs) of EBV miRNAs, including terminal isomiRs at both the 59
and 39 ends and nucleotide variants. Analysis of EBV genomic sequences indicated that the majority of EBV miRNA
nucleotide variants resulted from post-transcriptional modifications. Read counts of individual EBV miRNA in NPC tissue
spanned from a few reads to approximately 18,000 reads, confirming the wide expression range of EBV miRNAs. Several EBV
miRNAs were expressed at levels similar to highly abundant human miRNAs. Sequence analysis revealed that most of the
highly abundant EBV miRNAs share their seed sequences (nucleotides 2–7) with human miRNAs, suggesting that seed
sequence content may be an important factor underlying the differential accumulation of BART miRNAs. Interestingly, many
of these human miRNAs have been found to be dysregulated in human malignancies, including NPC. These observations
not only provide a potential linkage between EBV miRNAs and human malignancy but also suggest a highly coordinated
mechanism through which EBV miRNAs may mimic or compete with human miRNAs to affect cellular functions.
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Introduction
A unique feature of nasopharyngeal carcinoma (NPC) is its
strong association with Epstein-Barr Virus (EBV) [1]. EBV
genome can be detected in all cases of NPC, suggesting that
products of EBV genome are involved in the pathogenesis of this
malignancy. In addition to EBV-encoded protein-coding genes
such as EBNA1 and LMP1, latently infected NPC cells and tissues
also express high levels of non-coding EBV RNAs, including
EBER1, EBER2 and multiple microRNAs (miRNAs) [2,3,4,5].
EBV miRNAs were first identified by Pfeffer et al. via cloning of
small RNAs from a Burkitt’s lymphoma cell line latently infected
with EBV [6]. The authors identified six mature miRNAs derived
from five miRNA precursors in the EBV genome. Grundhoff et al.
subsequently identified 18 new precursors that produce 22 mature
miRNAs in EBV-infected Jijoye and BJAB cells by combining
computational and microarray approach [7]. Cai et al. also
identified additional EBV miRNAs from EBV-positive BC-1 cells
and demonstrated that the EBV miRNAs were conserved during
lymphocryptovirus evolution [8]. Recently, Zhu et al. used the
Roche 454 system to sequence ,2,000 reads of EBV miRNAs in
NPC tissues and discovered five novel mature EBV miRNAs [9].
To date, a total of 25 EBV miRNA precursors with 44 mature
miRNAs have been reported [10].
These EBV miRNA precursors are clustered in two regions of
the EBV genome. Three precursors (miR-BHRF1-1 to miR-
BHRF1-3) with four mature miRNAs are located within the
mRNA of the BHRF1 (Bam HI fragment H rightward open
reading frame 1) gene. An additional twenty-two precursors (miR-
BART1 to miR-BART22) with forty mature miRNAs are located
in intronic regions of the BART (Bam HI-A region rightward
transcript) transcript [6,7,8,9]. Studies using Northern blotting and
cloning methods have clearly documented two distinct expression
patterns of EBV miRNAs in EBV-infected B lymphoma cells and
EBV-positive NPC cell lines [6]. The expression of BHRF1
miRNAs can be detected only in lytically infected cells, whereas
expression of BART miRNAs can be detected in all forms of
latency. Recent studies by Cosmopoulos et al. using real-time PCR
technology confirmed the expression patterns observed in cell lines
and provided further insights into the wide expression range of
BART miRNAs in NPC clinical samples [11].
Recent studies imply that EBV miRNAs may be linked to the
pathogenesis of NPC. Functional studies revealed that these viral
miRNAs regulate EBV latent infection and modulate host immune
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example, BART2-5p miRNA has been shown to inhibit EBV lytic
replication by targeting the viral DNA polymerase BALF5 [12],
while BART1-5p, BART16-5p and BART17-5p have been found
to suppress the expression of the viral oncoprotein LMP1 [13]. On
the other hand, BHRF1-3 has been shown to modulate host
immune responses by targeting the interferon-induced chemokine
CXCL11 [14], while BART2-5p targets the host stress-induced
Natural Killer cell ligand, MICB, to escape recognition and
consequent elimination by NK cells [15]. Finally, BART5-5p has
been shown to promote host cell survival by targeting a pro-
apoptotic molecule, p53 up-regulated modulator of apoptosis
(PUMA) [16]. Together, these observations indicate that EBV
virus actively utilizes its miRNAs to flexibly manipulate various
viral and cellular functions.
To better understand the EBV miRNA transcriptome in NPC,
we took advantage of the massive parallel sequencing capability of
the SOLiD system and sequenced more than 110,000 reads of
EBV miRNAs in one pair of a clinical NPC tumor and its adjacent
normal samples. The abundance of sequence data allowed us to
thoroughly and confidently characterize these EBV miRNAs, to
determine their sequence and to assess their expression levels in
vivo. We (1) identified four new mature miRNAs derived from
known BART precursor hairpins; (2) observed extensive sequence
variations [17], including length heterogeneity and nucleotide
variations of EBV miRNAs and the wide expression range; some
of these variants are expressed at substantial levels and generate
additional seed sequences for EBV miRNAs; (3) revealed that most
of the highly abundant EBV miRNAs share their seed sequences
with human miRNA, suggesting a connection between seed
sequence content and the differential accumulation of these
miRNAs. More interestingly, several human miRNAs sharing seed
sequences with EBV miRNAs were found to be dysregulated in
NPC tissues, providing a potential linkage between EBV miRNAs
and human malignancy. Collectively, these data present a
comprehensive profiling of EBV miRNAs in a disease context
and implicate their pathological significance.
Materials and Methods
Clinical samples
Biopsy samples of NPC and adjacent normal nasopharynx tissue
were obtained from patients undergoing surgery. Tissues were
frozen immediately after surgical resection. Tissue specimens were
collected in accordance with the Institutional Regulation Board of
Chang Gung Memorial Hospital, Taiwan.
Cell lines
Two EBV-positive NPC cell lines, c666-1 and HK1-EBV, and
an EBV-negative NPC cell line, HK1, were kindly provided by
Dr. George Tsao. B95.8, Daudi and Namalwa are EBV-positive
Burkitt’s lymphoma cell lines. All cell lines were maintained in
RPMI-1640 medium supplemented with 10% fetal calf serum,
2 mM sodium pyruvate and 2 mM L-glutamate.
Preparation of total RNA
Total RNA from tissues and cultured cells was prepared using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. The concentration of purified RNA was
determined using a NanoDrop Spectrophotometer. The integrity
of the RNA was evaluated using an Agilent 2100 BioAnalyzer
(Agilent Technologies, Palo Alto, CA, USA). Aliquots of total
RNA were used directly for miRNA quantification using stem-
loop RT-PCR or subjected to small RNA library construction.
Small RNA library preparation
A small RNA library was prepared using the SOLiD small RNA
expression kit according to the manufacturer’s protocol. In brief, small
RNA was purified by polyacrylamide gel electrophoresis to enrich for
molecules in the range of 18–40 nt. One hundred nanograms of small
RNA was ligated to adaptors to the 59 and 39 termini of the RNA.
Ligated RNA was converted to cDNA, then digested with RNAse H
followed by PCR amplification. Amplified cDNA libraries were
purified on a 6% polyacrylamide gel and quantified. The cDNA
template (0.1 mg/uL) was subjected to emulsion PCR. Positive beads
were enriched and deposited onto slides. The cDNAs from these
libraries were sequenced using standard conditions for the SOLiD
system by Mission Biotech (Taipei, Taiwan).
Processing and analysis of deep sequencing data
Sequencing results were aligned to the reference human genome
(NCBI Build 36) and EBV genome (NC_007605) using standard
SOLiD mapping pipeline, allowing up to six mismatches out of
34 bp. All identical sequences were compiled to generate a data set
of the unique sequences with associated read counts. Only unique
sequences with read count greater than 2 were included for
subsequent annotation and analysis. Annotation of human and
EBV miRNA was based on the sequences registered in miRBase
(version13.0,http://www,mirbase.org/).Uniquelyalignedsequenc-
es with corresponding read counts were imported into Excel to
analyze terminal heterogeneity and nucleotide variation. Evolution-
ary conservation of miRNA was analyzed using the online mi-
Rviewer service (http://people.csail.mit.edu/akiezun/miRviewer/).
Sequence logos were generated using the online WebLogo sequence
logo generator (http://weblogo.berkeley.edu/logo.cgi).
Stem-loop real-time PCR
The design of the stem-loop RT primer was adopted from the
TaqMan miRNA assay described by Chen et al. [18]. For miRNA
quantification, each RT primer contains a stem-loop sequence to
enhance the binding specificity for mature miRNA and an 8-nt
overhang at the 39 end that complements the 39 end of individual
miRNA to prime the RT reaction. In some assays, 6-nt overhang
RT primers were used to analyze 39 terminal variants. EBV
BART miRNAs were reverse transcribed using a pulsed reverse
transcription reaction as described previously [18]. For each assay,
1 mg of total RNA was converted into cDNA in a 10-ml reaction
mixture containing miRNA-specific stem-loop RT primers (final
2 nM each), 500 mM dNTP, and 0.5 ml Superscript III (Invitro-
gen, Carlsbad, CA). The pulsed RT reaction was performed as
follows: 16uC for 30 min, followed by 50 cycles at 20uC for 30 s,
42uC for 30 s and 50uC for 1 s. RT products were diluted 20 fold
and used as the template in a 10 ml PCR reaction containing 1X
SYBR Master Mix (Applied Biosystems, Foster City, CA), 200 nM
miRNA-specific forward primer, and 200 nM universal reverse
primer. Real-time PCR was performed with the following
conditions: 95uC for 10 min, followed by 40 cycles of 95uC for
15 s and 63uC for 32 s, and a dissociation stage. Synthetic
miRNAs were reverse transcribed and amplified using the same
conditions to generate standard curves for copy number
calculation. All primers used are listed in the Table S1.
Results
EBV miRNA profiling and characterization in paired NPC
tumor and adjacent normal tissues
To profile EBV-encoded miRNAs in NPC, we used the ABI
SOLiD deep sequencing technology to characterize the EBV
EBV miRNAs in NPC
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(T10) was taken from the nasopharynx area with clinical evidence
of tumor. Clinically normal nasopharyngeal mucosa taken from
the same patient was used as the control tissue (N10). A total of
1.92610
7 and 2.36610
7 qualified reads were obtained from the
NPC tissue (T10) and the normal sample (N10), respectively
(Table 1). Among these reads, 5.87610
6 (,31%) from the T10
sample and 7.89610
6 (,33%) from the N10 sample could be
mapped to the human and EBV reference genome. After filtering
out tRNAs, rRNAs and genomic repeats, the remaining mappable
reads in the T10 sample contain 3.78610
5 reads corresponding to
570 known human miRNA hairpins. In the N10 sample,
1.42610
6 reads were mapped to 657 known human miRNA
hairpins. Compared to N10, the number of reads mapped to
known human miRNAs was much lower in T10. This result is
consistent with our previous observation that the expression level
of human miRNAs was significantly reduced in NPC samples
compared to normal tissues [19]. A global downregulation of
mature miRNAs in tumors compared with normal tissues has been
observed in many types of human cancer [20]. The global
downregulation of miRNAs in tumors is likely due to a decrease in
Dicer level in tumor samples [21,22].
EBV miRNA reads (1.33610
5 reads) constitute about 23.3% of
total miRNA reads in the T10 sample, indicating that viral
miRNAs take up a considerable portion of the miRNA biogenesis
machinery in NPC cells (Figure 1A). Among the 1.33610
5 EBV
miRNA reads, 85.5% of them were mapped to known EBV
miRNAs. In contrast, only 2.03610
3 reads (approximately 0.1% of
total miRNAs) from N10 were mapped to known EBV miRNAs.
As the RNA samples used in this study were not obtained by laser-
capture microdissection, the low level of EBV miRNAs detected in
the normal tissue is likely due to minor contamination of tumor
cells within the adjacent normal tissue. However, we could not
exclude the possibility that EBV-infected cells were present in
normal tissue adjacent to NPC. Our subsequent analysis focused
mainly on EBV miRNA reads detected in the T10 NPC sample.
The EBV small RNA reads detected in the T10 sample can be
separated into two distinct peaks based on the sequence length.
The major peak, spanning from 20 to 25 nts and centered at 22 nt,
correlated well with the size of mature miRNAs. A second peak
centered at 34 nt contained more than 90% of reads derived from
two EBV non-coding RNAs, EBER1 and EBER2 (Figure 1B).
These reads were likely derived from contamination of EBERs in
the small RNA library rather than microRNAs derived from the
EBER regions. First, the read length (34 nt) was much longer than
the size of mature miRNAs (,22 nt). Second, no hairpin structure
could be detected in these regions to demonstrate the structural
features that define a microRNA.
Although the EBV genome can be transcribed from both
directions, more than 99% of the EBV small RNA reads were
mapped to positive strand transcripts. Genomic locations of
all EBV small RNA reads in T10 are shown in Figure S1. These
EBV small RNAs were clustered in two genomic regions, the
EBER locus (6.6 kb–7.2 kb) and the BART locus (139 kb–
152 kb). A few small RNA reads were mapped to previously
unannotated regions, including the 70 kb and 153 kb regions of
the EBV genome. No sequencing read was mapped to the region
of BHRF1 transcripts. These results are in agreement with the
recent study of EBV miRNAs in NPC tissues using the Roche 454
technology [9].
Identification of novel EBV miRNAs
We identified 44 mature EBV miRNAs from 22 precursor
hairpins located in the BART region. Sequence information for
these BART miRNAs and their read counts in T10 and N10 are
summarized in Table 2. For clarity, -3p and -5p will be used to
identify mature BART miRNAs and to indicate their origin on the
corresponding precursor hairpin. Four mature miRNAs, including
BART12-5p, BART15-5p, BART16-3p, and BART22-5p, have
not been reported before. Secondary structure analysis confirmed
that these four novel miRNAs are located in the stem region of
their precursor hairpins (Figure S2). To confirm the presence of
these novel EBV miRNAs, we used a stem-loop real-time PCR
method to validate their expression in EBV-positive cell lines and
NPC tissues [18]. As expected, none of these miRNAs were
detected in the EBV-negative HK1 cells. In contrast, expression of
BART15-5p, BART16-3p and BART22-5p was readily detected
in two EBV-positive NPC cell lines, HK1-EBV and c666-1, and
two EBV-positive B-lymphoma cell lines, Daudi and Namalwa.
The EBV-positive B-lymphoma cells, B95.8, expressed significant
levels of BART15-5p, consistent with the deletion of the majority
of the BART locus in B95.8 genome [23] (Figure 2A). The low
level of BART22-5p detected in B95.8 was due to background
from the qPCR primer, as the gel electrophoresis did not detect a
corresponding product. Similarly, expression of these three novel
miRNAs was also readily detected in ten additional EBV-positive
NPC tissues but was very low in abundance or completely absent
in seven normal nasopharynx tissues (Figure 2B). Consistent with
the read counts from the deep sequencing data for T10, the real-
time PCR data indicated that expression levels of BART16-3p
were higher than BART15-5p and BART22-5p in all NPC tissues.
On the other hand, although BART12-5p was detected in the
SOLiD sequence, the real-time PCR method could not detect its
presence in majority of EBV-positive cell lines and NPC tissues.
Northern blot analysis further confirmed the presence of
BART16-3p in NPC tissues (Figure 2C). We were unable to
detect BART12-5p, BART15-5p and BART22-5p in NPC
samples with northern blotting due to their low abundance.
Interestingly, in the T10 sample, read counts of the newly
identified BART16-3p were higher than for BART16-5p, the
mature miRNA derived from the 5p stem of pre-miR-BART16
currently registered in miRBase [7]. To confirm the relative
abundance of these two mature miRNAs, we quantified their
absolute expression levels in 11 NPC tissues using real-time PCR.
As shown in Figure 2D, the absolute expression level of BART16-
3p is higher than that of BART16-5p in all NPC samples tested.
Table 1. Overview of small RNAs detected by SOLiD
sequencing.
Read
Type T10 (NPC) N10 (normal)
Total 19,254,966 23,605,814
Mapped to human & EBV genome 5,866,413 7,891,903
Mapped to human genome 5,733,273 7,888,388
human filters (tRNAs, rRNA, etc) 4,581,692 6,285,886
human miRNA (miRBase 12.0) 378,017 1,418,266
human others 1,151,581 1,602,502
Mapped to EBV genome 133,140 3,515
EBV miRNA (miRBase 12.0) 113,901 2,027
EBV others 19,239 1,488
human miRNAs + EBV miRNAs 491,918 1,420,293
doi:10.1371/journal.pone.0012745.t001
EBV miRNAs in NPC
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fold higher than that of BART16-5p, similar to the read count
ratio detected in T10 (Table 2). These data suggest that in NPC
samples, BART16-3p is the predominant form of mature miRNA
derived from the BART16 precursor hairpin.
Length and sequence variations of EBV-encoded miRNAs
The EBV miRNA sequences obtained from deep sequencing
exhibited a high degree of deviation from their miRBase
‘‘reference’’ sequences. Of the ,113,000 EBV miRNA reads,
only 22% of reads could be exactly aligned to the mature EBV
miRNA sequence in the miRBase. Another 21% of the reads had
sequence matches to the reference EBV miRNA but exhibited
terminal heterogeneity at the 39 and/or 59 ends. The remaining
57% of reads exhibited one- to three-nucleotide variations from
the reference EBV miRNA sequences in miRBase. The presence
of miRNA variants, including length heterogeneity and nucleotide
variations, referred to as isomiRs, has been described in previous
studies using different deep sequencing technologies. The large
abundance of length and sequence variants of EBV miRNA
indicate that some of these isomiRs should be considered as the
reference miRNA, at least in NPC tissue. We found 20 EBV
miRNAs whose miRBase reference sequences represented the
most abundant form of EBV miRNAs detected in the NPC tissue.
In contrast, the reference sequences for six miRNAs, including
BART2-3p, BART3-5p, BART5-3p and -5p, BART10-5p and
BART16-5p, were not even detected. The extent of length
heterogeneity and nucleotide variation observed in our EBV
miRNA deep sequencing study was similar to that observed in
miRNAs from Rhesus lymphocryptovirus (rLCV) [24] and
Kaposi’s sarcoma-associated herpesvirus (KSHV) [25], as well as
in human and mouse miRNAs [17,26,27].
Figure 3A shows the sequences and read counts for BART3-3p
and BART10-3p with alternative 39 and 59 ends (length isomiRs)
detected in the T10 sample. The complete set of length isomiRs
for all EBV miRNAs is shown in Table S2. Length variations of
EBV miRNA were found at both the 59- and 39-ends. The
frequency of 59 end length variations for all EBV miRNAs was less
than 5% and typically limited to plus or minus two nucleotides
(Figure 3B). In contrast, the average frequency of 39-end length
variants for all EBV miRNAs was greater than 50% and spanned
from minus 4 to plus 4 nucleotides (Figure 3C). To confirm the
presence of length isomiRs for EBV miRNA in NPC, we designed
a series of stem-loop RT primers, each of which recognized the last
6 nucleotides at the 39-end of a specific length isomiR, and used
RT-PCR to amplify individual length isomiRs. The PCR products
were then separated on polyacrylamide gels to resolve the length
heterogeneity. Synthetic miRNAs with 39-end length heterogene-
ity were used to validate the sensitivity and specificity of these RT
primers (Figure S3). The results shown in Figure 3D demonstrated
the presence of various 39-end length isomiRs of BART5-5p in the
T10 sample.
In addition to the length variations, more than 50% of the EBV
miRNA deep sequencing reads exhibited one- to three-nucleotide
mismatches to the reference sequence of EBV miRNA. Figure 4A
shows a partial list of nucleotide variants of BART19-3p and
BART3-3p. Similar to the length variation, the majority of
nucleotide variation occurred in the 39-end region, with significant
variations observed in nt 17–23 of mature miRNAs. The average
frequency of nucleotide variation for all EBV miRNA is shown in
Figure 4B. Two lines of evidence suggest that the nucleotide
variation observed in our current study is not an artifact of either
the sequencing technology or the data-processing algorithm of the
SOLiD platform. First, the nucleotide variations display a non-
random pattern, with extremely low variation frequency within the
miRNA seed region (nt 2–7) and low variation frequency in the
miRNA cleavage/anchor region (nt 10–16). Secondly, the average
variant frequency observed for the degradation products of EBERs
detected from the same sequencing run is less than 1% across the
entire 34-nt read length. Furthermore, the degree of nucleotide
variation of EBV miRNAs in NPC detected with SOLiD is similar
to the rLCV miRNAs sequencing data obtained by Riley et al.
using the Illumina Solexa platform [24]. The complete set of
nucleotide isomiRs for all EBV miRNAs is shown in Table S3.
Table S4 summaries the sequences and read counts for major
EBV miRNAs detected in the T10 sample.
To clarify the source of nucleotide variations observed in EBV
miRNAs, we sequenced the EBV genomic region corresponding
to all BART miRNAs in five different NPC tissues and two NPC
cell lines, HK1-EBV and c666-1. Given the heterogeneous nature
Figure 1. Overview of human and EBV miRNAs detected in NPC samples. (A). Proportion of human and EBV miRNAs detected in T10 and
N10 libraries. Read counts represent total reads mapped to miRBase-registered precursor hairpins for human and EBV miRNAs. (B). Size distribution of
EBV small RNAs detected in T10 sample.
doi:10.1371/journal.pone.0012745.g001
EBV miRNAs in NPC
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EBV miRNA miRBase Name miRBase
a Sequence
b Start End Offset
c T10
d T10
e N10
d
BART3-5p BART3* 12 AACCTAGTGTTAGTGTTGTGC 139086 139106 21, 214 3 2 4 5 3
BART3-3p BART3 12 CGCACCACTAGTCACCAGGTGT 139124 139145 0,0 6064 17990 120
BART4-5p BART4 12 GACCTGATGCTGCTGGTGTGCT 139228 139249 0,0 1622 9204 33
BART4-3p BART4* 13 CACATCACGTAGGCACCAGGTGT 139266 139288 0,0 66 128 0
BART1-5p BART1-5p 12 TCTTAGTGGAAGTGACGTGCTGTG 139351 139374 0,0 18 462 8
BART1-3p BART1-3p 12 TAGCACCGCTATCCACTATGTC 139387 139408 0,0 674 5551 3
BART15-5p novel AGGGAAACATGACCACCTGAAGTC 139519 139542 0,0 3 3 0
BART15-3p BART15 12 GTCAGTGGTTTTGTTTCCTTGA 139553 139574 0,0 1212 1894 50
BART5-5p BART5 12 CAAGGTGAATATAGCTGCCCATCG 139675 139698 0,0 2601 15654 64
BART5-3p BART5* 13 GTGGGCCGCTGTTCACCTAA 139717 139736 0,2 110 300 0
BART16-5p BART16 12 TTAGATAGAGTGGGTGTGTGCTC 139795 139817 0,219 1 2 1 0
BART16-3p novel ATCACCACCCTCTATCCATAT 139836 139856 0,0 199 705 0
BART17-5p BART17-5p 12 TAAGAGGACGCAGGCATACAA 139915 139935 0,213 8 1 9 4 0
BART17-3p BART17-3p 12 TGTATGCCTGGTGTCCCCTTAGT 139953 139975 0,0 664 1568 9
BART6-5p BART6-5p 12 TAAGGTTGGTCCAATCCATAGG 140033 140054 0,0 15 1482 0
BART6-3p BART6-3p 12 CGGGGATCGGACTAGCCTTAGA 140072 140093 0,0 430 1865 9
BART21-5p BART21-5p 13 TCACTAGTGAAGGCAACTAAC 145514 145534 0,0 36 159 0
BART21-3p BART21-3p 13 CTAGTTGTGCCCACTGGTGTTT 145548 145569 0,0 9 16 0
BART18-5p BART18-5p 12 TCAAGTTCGCACTTCCTATACA 145962 145983 0,0 290 1853 4
BART18-3p BART18-3p 12 TATCGGAAGTTTGGGCTTCGTC 145998 146019 0,0 8 44 0
BART7-5p BART7* 12 CCTGGACCTTGACTATGAAACA 146439 146460 0,0 112 276 0
BART7-3p BART7 12 CATCATAGTCCAGTGTCCAGGG 146475 146496 0,0 197 8313 5
BART8-5p BART8 12 TACGGTTTCCTAGATTGTACAG 146772 146793 0,0 1532 2498 49
BART8-3p BART8* 12 GTCACAATCTATGGGGTCGTAGA 146807 146829 0,0 1499 4869 26
BART9-5p BART9* 12 TACTGGACCCTGAATTGGAAAC 146959 146980 0,0 29 191 0
BART9-3p BART9 12 TAACACTTCATGGGTCCCGTAGT 146997 147019 0,0 5266 16398 77
BART22-5p novel TGCTAGACCCTGGAGTTGAACC 147169 147190 0,0 5 10 1
BART22-3p BART22 13 TTACAAAGTCATGGTCTAGTAGT 147203 147225 0,0 167 534 6
BART10-5p BART10* 12 GCCACCTCTTTGGTTCTGTAC 147321 147341 0,218 1 1 5 8 3
BART10-3p BART10 12 TACATAACCATGGAGTTGGCTGT 147356 147378 0,0 171 3633 4
BART11-5p BART11-5p 12 TCAGACAGTTTGGTGCGCTAGTTG 147537 147560 0,0 30 350 1
BART11-3p BART11-3p 12 ACGCACACCAGGCTGACTGCC 147575 147595 0,0 70 918 1
BART12-5p novel ACCCGCCCATCACCACCGGAC 147901 147921 0,0 19 82 0
BART12-3p BART12 12 TCCTGTGGTGTTTGGTGTGGTT 147936 147957 0,0 16 142 0
BART19-5p BART19-5p 12 ACATTCCCCGCAAACATGACATG 148215 148237 0,0 13 7713 0
BART19-3p BART19-3p 12 TTTTGTTTGCTTGGGAATGCT 148254 148274 0,0 3 36 0
BART20-5p BART20-5p 12 TAGCAGGCATGTCTTCATTCC 148339 148359 0,0 3 6 0
BART20-3p BART20-3p 12 CATGAAGGCACAGCCTGTTACC 148374 148395 0,0 99 166 4
BART13-5p BART13* 12 AACCGGCTCGTGGCTCGTACAG 148526 148547 0,0 35 333 1
BART13-3p BART13 12 TGTAACTTGCCAGGGACGGCTGA 148563 148585 0,0 32 334 1
BART14-5p BART14* 12 TACCCTACGCTGCCGATTTACA 148744 148765 0,0 27 360 1
BART14-3p BART14 12 TAAATGCTGCAGTAGTAGGGAT 148778 148799 0,0 13 93 0
BART2-5p BART2-5p 12 TATTTTCTGCATTCGCCCTTGC 152747 152768 0,0 605 1470 6
BART2-3p BART2-3p 12 AAGGAGCGATTTGGAGAAAATAA 152783 152805 0,21 8 12 0
a : miRBase version or novel miRNA.
b:5 9 to 39.
c:5 9 and 39 terminal position deviated from miRBase RefSeq.
d : Number of times the exactly matched sequence detected.
e : Number of times total sequence detected.
doi:10.1371/journal.pone.0012745.t002
EBV miRNAs in NPC
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12745Figure 2. Detection and quantification of novel EBV miRNAs in cell lines and NPC tissues. (A). Expression of novel EBV miRNAs in NPC and
B lymphoma cells. Expression of BART12-5p, BART15-5p, BART16-3p and BART22-5p was quantified using real-time PCR in EBV-positive cells,
including HK1-EBV and c666-1 NPC carcinoma cells and B95.8, Daudi and Namalwa B lymphoma cells. HK1 is an EBV-negative NPC carcinoma cell line.
Expression levels of miRNA were expressed as molecules per ng total RNA. (B). Expression of novel EBV miRNAs in normal and NPC tissues. Total RNAs
from 11 NPC tissues and 8 adjacent normal tissues were analyzed for novel EBV miRNA expression using real-time PCR method. Expression levels of
miRNA were expressed as molecules per ng total RNA. PCR products were analyzed using 10% polyacrylamide gel. Human miRNA hsa-miR-103, a
EBV miRNAs in NPC
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12745ubiquitously expressed miRNA, was used as a loading control. (C). Northern blot detection of BART16-3p in NPC and adjacent normal tissues. Total
RNA (5 mg) isolated from NPC tissues and adjacent normal tissues was separated in 12.5% denaturing polyacrylamide gels and analyzed with DIG-
labeled LNA probes specific for the indicated miRNAs. RNAs from sample N10 and N12, N16 and N18 were pooled and used as normal tissues. (D).
Expression level of BART16-5p and BART16-3p in NPC tissues. Expression levels of BART16-5p and BART16-3p were quantified in 11 NPC tissues using
real-time PCR. P-value was calculated with paired-t-test (two-tailed).
doi:10.1371/journal.pone.0012745.g002
Figure 3. Length isomiRs of EBV BART miRNAs in T10. (A). Examples of length isomiRs of EBV miRNA BART3-3p and BART10-3p. Shown are the
isomiR sequences and read counts detected in the T10 sample. (B). Distribution of 59-end heterogeneity of EBV BART miRNA in T10. To analyze the 59-
end heterogeneity, each miRNA isomiR was aligned to its corresponding miRBase reference sequence to calculate the 59-end nucleotide offset.
IsomiRs with 59-end nucleotide extension relative to the miRBase reference were assigned a negative offset number, while isomiRs with nucleotide
deletion at the 59-end were assigned a positive offset number. The frequency of 59 terminal heterogeneity for each miRNA was calculated by dividing
the read count at each alternative end by the total read count and was expressed as terminal variation frequency. Shown are the mean frequency 6
SD calculated using 35 EBV BART miRNAs whose total reads exceed 100 in the T10 sample. (C). Distribution of 39-end heterogeneity of EBV BART
miRNAs in T10. A similar strategy was used to calculate the 39-end nucleotide offset for each miRNA isomiR. The frequency of 39 terminal
heterogeneity for each miRNA was calculated by dividing the read count at each alternative end by the total read count and was expressed as
terminal variation frequency. Shown are mean frequency 6 SD calculated using 35 EBV BART miRNAs whose total reads exceed 100 in T10 sample.
(D). Validation of BART5-5p 39-end isomiRs in T10 sample. Sequence and read counts of the representative 39 terminal isomiRs of BART5-5p are shown
in the left panel. Nucleotides used to design stem-loop RT primer for each terminal isomiR (N to N-4) are underlined. PCR products of individual
isomiR from T10 sample were analyzed using 15% polyacrylamide gel electrophoresis. To highlight the size difference of individual isomiRs, PCR
products generated from N and N-4 primer were mixed and run on both sides to serve as size markers.
doi:10.1371/journal.pone.0012745.g003
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variants detected in EBV microRNAs arose from genomic
mutations in the tumor cell population. For each tumor sample,
multiple clones were sequenced to address the potential hetero-
geneity of the EBV genome in tumor tissues. We did not find any
sequence polymorphism in the genomic region of mature EBV
miRNAs except for BART19-5p (Figure 5A). In four of the five
NPC tissues and in c666-1 cells, we detected a T to C nucleotide
change at the position of 148,231 of the EBV reference genome,
corresponding to nt 17 of the mature BART19-5p. This
polymorphism was reflected in the deep sequencing data with a
.90% variation frequency in nt 17 of BART19-5p reads
(Figure 5B). To further compare the sequence identity between
the genomic and miRNA levels, we converted the aligned genome
sequence as well as the miRNA sequences of BART3-3p and
BART19-5p into the sequence logo [28]. As shown in Figure 5C,
significant nucleotide variation occurred in the last six nucleotides
of the 39end of both mature EBV miRNAs, while no such
nucleotide variation was found in the EBV genomic DNA. These
data indicate that the majority of the nucleotide variants of EBV
miRNAs detected in deep sequencing were the results of post-
transcriptional modifications.
Expression Levels of EBV miRNAs in NPC tissues
As our sequence analysis shows that EBV miRNAs exist with
multiple length and nucleotide variants, we decided to use the total
read, including all length and nucleotide variants, to represent the
abundance of individual EBV miRNAs in NPC tissue. As shown in
Figure 6A, the read counts of individual EBV miRNAs in the T10
sample spanned from a few reads to approximately 18,000 reads.
Figure 4. Nucleotide variations of EBV BART miRNAs. (A) Examples of nucleotide variants of BART3-3p and BART19-5p. Shown are the partial
list of sequences and read counts of nucleotide variants detected in the T10 sample. Nucleotides deviated from the miRBase reference sequence are
shown in lower case letters. (B) Distribution of nucleotide variation along the nucleotide positions of EBV miRNA. For individual EBV miRNAs, all
sequence variants were aligned to the miRBase reference sequence to determine the nucleotide variation at each position. The variation frequency
for each miRNA at each position was calculated by dividing the mismatched reads at each position by total reads. The average variation frequency of
EBV miRNA at each position was calculated from 35 EBV BART miRNAs whose total reads exceed 100 in the T10 sample. A similar calculation was
performed to determine the nucleotide variation frequency at each position of two EBV non-coding RNAs, EBER1 and EBER2. The frequency of
nucleotide variation of EBERs and EBV miRNAs at each position was plotted on the same scale to highlight the pattern and the extent of nucleotide
variation of EBV miRNAs. The nucleotide variation of EBV miRNA was clearly suppressed from nucleotides 2 to 14, covering the seed sequence and
the potential miRNA:mRNA binding regions.
doi:10.1371/journal.pone.0012745.g004
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including BART3-3p, BART5-5p and BART9-3p, all exceeded
the read count of miR-21(data not shown), a highly abundant
human oncogenic miRNA. To validate the relative abundance of
these EBV miRNAs derived from deep sequencing reads, we
designed stem-loop real-time PCR primers for 25 EBV miRNAs,
including high and low expressors, and quantified their expression
levels in the T10 sample (Table S5). As shown in Figure 6B, the
data from real-time PCR are highly correlated with the total reads
from SOLiD sequencing (Pearson’s correlation coefficient =0.83).
Both technologies show that the expression levels of these EBV
miRNAs span approximately 2,000-fold in the T10 sample. To
ensure that the relative abundance of EBV miRNAs was not
sample-dependent, we quantified the expression levels of these 25
BART miRNAs in 12 additional NPC tissues and c666-1 cells and
analyzed the correlation of EBV miRNA expression pattern
among these samples. Correlation coefficients among these NPC
samples were all greater than 0.8 even though the absolute
expression levels of EBV miRNAs varied substantially in
individual samples (Figure 6C). These data indicate that the
overall expression patterns of BART miRNAs were highly similar
across all NPC tissues and cell lines.
Highly abundant EBV miRNAs shared seed sequence with
human miRNAs
The high expression levels of EBV miRNAs suggest that they
may play important roles in regulating viral as well as cellular
function. It is well recognized that the target spectrum of a miRNA
is largely determined by its seed sequence. We hypothesized that
the degree of seed-sequence homology between human and EBV
Figure5. Nucleotidevariations of EBV genomic DNA andBART miRNAs in NPCsamples. (A) Example of genomic sequence of BART3-3p and
BART19-5p in NPC cell lines and tissues. Genomic DNA from HK1-EBV, c666-1 cells and five NPC tissues was sequenced and compared to three EBV
genomicsequencesdepositedin theGenBank,includingthereferencesequenceof the EBVgenome(RefSeq),AG876andGD1.No nucleotidemismatch
was found for BART3-3p in all NPC samples. A T to C nucleotide polymorphism at nt 17 of BART19-5p was found in c666-1 and four of the five NPC
tissues. (B) Frequency of nucleotide variation in BART3-3p and BART19-5p miRNA detected in T10. For BART3-3p and BART19-5p, the frequency of
nucleotide variation at each position was calculated by dividing the mismatched reads at each position by total reads. A greater than 90% variation
frequency was detected at nt 17 of BART19-5p, corresponding to the T/C polymorphism found in the genomic sequence. (C) Sequence logos of BART3-
3p and BART19-5p genomic DNA and miRNAs. DNA sequence logos were generated using all of the genomic sequences listed in Figure 5A, including
three EBV genome sequences from GenBank and seven sequences from NPC samples. MiRNA sequence logos were generated using sequences of all
unique isomiRs for BART3-3p and BART19-5p. Sequence logos represent the frequency of nucleotides detected at each position.
doi:10.1371/journal.pone.0012745.g005
EBV miRNAs in NPC
PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12745miRNAs might reveal potential interaction between viral and
human miRNAs. We therefore compared the seed sequences of all
mature BART miRNAs to the seed sequences of all known human
miRNAs (Lewis et al. 2005). There are 642 unique 6-mer seed (nt
2–7) sequences for all 988 human miRNAs registered in miRBase
[29]. The expected seed-sharing probability between all EBV and
all human miRNAs is 15.7%. We found that 13 of the 44 BART
miRNAs shared identical seed sequences with 21 human miRNAs
(Table 3). The observed seed-sharing percentage is 29.2%, about
two-fold higher than the expected value. Interestingly, the seed-
sharing frequency is not evenly distributed when the abundance of
EBV miRNAs is taken into consideration. Six of the 10 most
abundant EBV miRNAs shared their seed sequences with a total
of 11 human miRNAs. In contrast, only one of the 10 least
abundant EBV miRNA shared its seed sequence with 2 human
miRNAs. The observed connection between seed-sequence
sharing and EBV miRNA abundance suggest that seed-sequence
content is an important factor in determining the differential
accumulation of these EBV miRNAs. Moreover, the expression
level of the miR-18 family (sharing seed with BART5-5p) was up-
regulated in NPC, and expression levels of the miR-29 family
(sharing seed with BART1-3p) and miR-200 family (sharing seed
with BART9-3p) were down-regulated in NPC tissues (Figure 7)
[19,30]. These observations suggest that EBV miRNAs may
influence critical cellular functions by either mimicking or
competing with human miRNAs.
Discussion
Previous studies have identified 25 miRNA precursor hairpins
in the EBV genome, three located in the BHRF1 region and 22 in
the BART region [6,7,8,9]. To better understand the roles of these
EBV-encoded miRNAs in the pathogenesis of NPC, we used the
deep sequencing technology to interrogate the EBV miRNA
transcriptome in clinical NPC tissues. Although the total reads for
the BART miRNAs exceeded 110,000 in the T10 sample, no
Figure 6. Expression levels and seed sequence conservation of EBV BART miRNAs in NPC samples. (A) Read counts of all EBV miRNAs
detected in T10. Read counts for each miRNA include all terminal isomiRs and nucleotide variants. (B) Correlation between SOLiD read counts and
real-time PCR expression levels of EBV miRNAs detected in T10. Twenty-five BART miRNAs in the T10 sample were quantified using real-time PCR.
Expression levels of miRNA are expressed as molecules per ng total RNA. To calculate the correlation, total reads from SOLiD sequence and expression
levels from real-time PCR were log2-transformed and analyzed using Person’s correlation analysis. Pearson’s correlation coefficient and p-value are
shown in the inserts. (C) Conservation of BART miRNA expression pattern in NPC tissues and cell lines. Expression levels of 25 BART miRNAs in 13 NPC
tissues and c666-1 cells were quantified using real-time PCR. Correlation analysis was performed on log2-transformed data to determine the similarity
of BART miRNA expression patterns among these samples. Data shown in the lower left portion are Pearson’s correlation coefficients. Values shown
in the upper right portion are Spearman’s correlation coefficients. Both correlation analyses show a high degree of similarity in BART miRNA
expression patterns among these NPC samples and c666-1 cells.
doi:10.1371/journal.pone.0012745.g006
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tion that BHRF1 is specifically expressed in EBV-positive B cells
[9,11]. We detected 44 mature EBV miRNAs derived from 22
distinct precursor hairpins in the BART region. Four of the
mature EBV miRNAs have not been reported in previous studies
using cloning or a deep sequencing method. These newly
identified mature BART miRNAs, together with the 40 known
BART miRNAs, established a complete BART miRNA tran-
scriptome in NPC, with two mature miRNAs produced by each
precursor hairpin. The EBV miRNA transcriptome in NPC is very
similar to the viral miRNA transcriptome of the closely related
rLCV [31]. One of the novel EBV miRNAs detected in the
present study, BART15-5p, was previously predicted by Walz et
al. based on the results from the rLCV study [31].
Table 3. EBV miRNAs sharing seed sequence with human miRNA.
EBV miRNA Reads
a Seed Human miRNAs
b Conservation
c in NPC
d Biological function and significance of human miRNAs
BART3-3p 17990 GCACCA miR-767-5p Mammals rLCV nd
e
BART9-3p 16398 AACACU miR-141, -200a Invertebrates rLCV down Inhibit EMT transition, cell growth, pluripotency & cancer
progression Down-regulated in many solid tumors
BART5-5p 15645 AAGGUG miR-18a, -18b Vertebrates rLCV up Member of miR-17-92 cluster Oncogenic microRNA
BART7-3p 8313 AUCAUA miR-154*, -487a Mammals rLCV nd
e Expressed in human embryonic stem cells
BART1-3p 5551 AGCACC miR-29a, -29b, -29c Vertebrates rLCV down Suppress DNA methylation, apoptosis and cell migration Down-
modulated in various type of cancer
BART8-3p 4869 UCACAA miR-513b primates no change Involved in IFN-r pathway
BART22-3p 534 UACAAAG
f miR-520d-5p, -524 primates nd
e Expressed in undifferentiated human embryonic stem cells
BART11-5p 350 CAGACAG
f miR-1324 Primates rLCV nd
e Cloned from neuroblastoma
BART7-5p 276 CUGGAC miR-378, -422a Mammals rLCV no change Promote cell survival, tumor growth and angiogenesis
BART9-5p 191 ACUGGA miR-1243 rLCV nd
e
BART12-3p 142 CCUGUG miR-1914 rLCV nd
e
BART4-3p 128 ACAUCAC
f miR-499-3p Vertebrates rLCV nd
e Heart-specific miRNA
BART2-3p 12 AGGAGC miR-28-5p, -708 Mammals rLCV no change Dysregulated in bladder cancer
BHRF1-1
g 0 AACCUG miR-490-3p, -649 Vertebrates rLCV nd
e
a : Total read counts in the T10 sample.
b : Human miRNAs with identical seed sequence (2-7 nt).
c : Conservation scope of the seed sequence, data compiled from miRiewer.
d : Expression level of human miRNAs in NPC tissues.
e : Not determined.
f : Share 7-mer seed sequence (nt 2–8).
g : Highly abundant EBV miRNA in EBV-positive B lymphomas.
doi:10.1371/journal.pone.0012745.t003
Figure 7. Expression levels of human miRNAs sharing seed sequences with highly abundant EBV BART miRNAs in NPC samples. (A)
Sequence alignments between EBV miRNAs and human miRNAs. Seed sequences are underlined. (B) Expression levels of human miRNAs miR-18a,
miR-18b, miR-200a and miR-29c in 9 normal and 13 NPC clinical tissues. The miRNA expression levels are presented as 39– Ct after normalization to
u6 small RNA. P-values were calculated using t-test. Shown are the means 6 sd.
doi:10.1371/journal.pone.0012745.g007
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heterogeneity and sequence variations of EBV miRNAs in NPC
tissue. These length and nucleotide variants constitute more than
50% of the total EBV miRNA reads, and many sequences show
significant deviation from the miRBase reference sequence. Such
length and sequence heterogeneity was not reported in a previous
study that used the Roche 454 platform to sequence EBV miRNAs
in two NPC tissues [9]. This discrepancy was mainly due to
differences in the stringency of the data-processing algorithm. The
data-processing algorithm used by Zhu et al. in the previous study
did not allow any sequence deviation from the miRBase reference
sequence [9]. However, similar length and sequence heterogeneity
was reported in several recent studies using various technologies to
sequence viral miRNAs [24,25]. The miRNA sequences detected
in these studies also show significant deviation from the reference
sequence deposited in miRBase. Recently, de Hoon et al.
discovered that cross-mapping may contribute to the sequence
heterogeneity observed in data obtained from high-throughput
sequencing libraries and proposed that a correcting algorithm
might be useful to reduce potential error caused by cross-mapping
[32]. However, the impact of cross-mapping on EBV miRNA
sequencing data is probably minimal, as sequence similarity
among EBV miRNAs is much lower than the sequence similarity
observed in human miRNAs from the same miRNA family.
Length heterogeneity of EBV miRNAs was detected in both the
59- and 39-ends of mature miRNAs. However, the extent of length
heterogeneity is significantly lower in the 59-end, reflecting a better
preservation of the 59 sequence. The asymmetric length heteroge-
neity was observed in all EBV miRNAs, regardless of whether they
were produced from the 3p arm or the 5p arm of the precursor
hairpin. A similar phenomenon was reported in two recent studies
using the Solexa platform to sequence viral miRNAs in latently
KSHV-infected BC-3 B-cell line [25] and latently rLCV-infected
monkey B cells [24]. Furthermore, the extent of asymmetric length
heterogeneity observed in mature miRNAs encoded by KSHV,
rLCV and EBV is very similar to that of human miRNAs from
brain tissues [33]. Because length heterogeneity in the 59-end will
change the seed sequence and have a profound impact on the target
spectrum, miRNAs are under selection pressure to maintain their
seed sequences. Recent studies suggest that the conservation of
miRNA 59 termini was maintained by the selective loading of
miRNA into the Argonaute complex [34].
Widespread sequence variants were detected for all 44 EBV
BART miRNAs, with the counts of sequence variants for each
miRNA roughly parallel to their total reads in the T10 sample.
These sequence variants contain one- to three-nucleotide
mismatches to the reference EBV genome, and the vast majority
of nucleotide variations were detected at the 39-end region, from
nt 17 to nt 24. Extensive nucleotide variations in rLCV miRNAs
have recently been reported by Riley et al. in latently rLCV-
infected monkey B-cells using the Solexa sequencing platform
[24]. Similar nucleotide variations have been reported on human
brain miRNAs from normal samples, Huntington’s disease brain
regions [33] and neuroblastoma tissues [35], as well as on mouse
let-7 miRNAs from ovarian tissues using both SOLiD and the
Solexa sequencing platform [27]. The distribution pattern of
nucleotide variations observed for EBV miRNAs in NPC is very
similar to the pattern reported for human miRNAs from brain
tissues, except that we did not find any increase in nucleotide
variation in the bulge region (9–12 nt) [33]. This discrepancy
could be due to the difference in the miRNA population studied.
Several mechanisms, including nucleotide polymorphism in the
EBV genome and post-transcriptional modifications, could con-
tribute to the sequence variations observed in EBV miRNAs.
Indeed, one sequence polymorphism was detected in the BART
region oftheEBV genome.A T to Cnucleotidepolymorphism atnt
17 of BART19-5p was detected in four out of five clinical NPC
samples and in the c666-1 NPC cells. While nucleotide polymor-
phism could account for the dramatic sequence variation observed
in this particular site, the remaining sequence variations detected in
EBV miRNAs probably resulted from post-transcriptional modifi-
cations. Recent studies have confirmed that RNA editing [36,37]
and non-template extension [26] are common post-transcriptional
modifications, and these mechanisms could account for the wide
diversity of sequence variations observed in mature EBV miRNA.
Although the biological implications of these extensive modifica-
tions remain to be elucidated, adenylation at the 39-end has been
shown to enhance the stability of mature miRNAs [38].
Although all BART miRNAs were transcribed from the same
BART transcripts [39], their read counts in the T10 sample spanned
over 2000-fold, ranging from a few reads to close to 18,000 reads.
T h ew i d er a n g eo fB A R Tm i R N Ar e a d sd e t e c t e dw a sc o n f i r m e d
using real-time PCR technology. This result is in agreement with two
recent studies using TaqMan-based real-time PCR technology to
quantify EBV miRNAs in EBV-positive cell lines [40] and NPC
tissues [11]. A recent study by Pratt et al. [40] measuring the
expression of 8 BART miRNAs in 17 EBV-positive cell lines also
revealed that although the absolute levels of these miRNA differ
among EBV-infected cells, the ranked order of the levels of individual
BART miRNAs are similar among these cell lines. Therefore, the
differential expression pattern of BART miRNAs seems to be
independent of the cell types and the latency stages of EBV infection.
The relative abundance of some EBV miRNAs detected in current
study is different from the results of the study conducted by
Cosmopoulos et al. [11]. This discrepancy is due to that two different
methods were used to calculate the abundance for individual EBV
miRNA. In the study conducted by Cosmopoulos et al., RT-PCR
was used to quantify the expression level of only the miRBase RefSeq
forindividualEBVmiRNA.However,inthepresentstudy,totalread
count, including all length and sequence isomiRs, was used to
represent the abundance for each EBV miRNA.
Although several hypotheses have been postulated, the mech-
anisms governing the differential accumulation of individual
BART miRNAs in EBV-infected cells remain unclear. Interest-
ingly, we observed that six out of the ten most abundant EBV
BART miRNAs share seed sequences with miRNAs that are
evolutionally conserved from rLCV, to drosophila, to human. It is
possible that these highly abundant EBV miRNAs may arise from
a selection process driven by the virus to actively mimic human
miRNAs in order to take control of critical biological functions of
host cells [41,42]; alternatively, the conserved seed sequences may
play an active role in stabilizing these highly abundant BART
miRNAs. This observation is consistent with a previous report that
highly conserved human miRNAs are expressed at higher levels
than non-conserved miRNAs [43]. In particular, the miR-200
family (shares seeds with BART9-3p), the miR-29 family (shares
seeds with BART1-3p) and miR-18 (shares seeds with BART5-5p)
are expressed at high levels in major types of human tissues and
cell lines [44] and are highly conserved during evolution [43]. As
miRNA concentration is a function of biogenesis and turnover,
active miRNA degradation might also regulate miRNA accumu-
lation. Recently, Chatterjee and Grosshans found that, in
Caenorhabditis elegans, miRNAs that are not associated with
targets were released from Argonaute and exposed to degradation
by exonucleases [45]. These results suggest that target availability
can stabilize the association of a miRNA with Argonaute and
protect the miRNA from degradation. Previous studies have
shown that conserved miRNAs typically were expressed more
EBV miRNAs in NPC
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addition, broadly expressed conserved miRNAs tend to have more
predicted targets than conserved miRNAs with more restricted
expression [46]. It is reasonable to assume that those EBV BART
miRNAs that share seeds with highly conserved and broadly
expressed human miRNAs would have more cellular targets and
be better protected by the Argonaute complex, leading to their
accumulation in the EBV-infected cells.
Read counts of the three most abundant EBV BART miRNAs,
BART3-3p, BART5-5p and BART9-3p, all exceeded 15,000,
similar to the level of a highly abundant human oncogenic
miRNA, miR-21, in the T10 sample. BART5-5p has been shown
to regulate a human pro-apoptotic target, p53 up-regulated
modulator of apoptosis (PUMA), and promote the survival of NPC
cells against etoposide-induced apoptosis [16]. The seed sequence
of BART5-5p is identical to the seed sequence of two human
miRNAs, hsa-miR-18a and miR-18b, which are members of the
oncogenic miR-17-92 cluster. This oncogenic miRNA cluster is
overexpressed in many types of human malignancy and promotes
tumor formation when ectopically expressed in animals [47,48].
Our previous study using real-time PCR also found that the
expression levels of miR-18a and miR-18b were significantly up-
modulated in NPC tissues [19].
The biological functions of BART9-3p have not been
established. However, we found that the seed sequence of
BART9-3p is identical to the seed sequence of the human miR-
200 family, including miR-200a and miR-141. Recent studies
clearly established the role of miR-200-family miRNAs in the
control of epithelial-to-mesenchymal transition (EMT), a biolog-
ical process involved in tumor metastasis [49,50]. Down-regulation
of the miR-200 family is observed in many solid tumors
[51,52,53]. The expression level of miR-200a was found to be
significantly reduced in NPC tissues [19]. In addition, another
highly abundant EBV miRNA, BART1-3p, also shared its seed
sequence with the miR-29 family, including miR-29a, -29b, and -
29c. Expression levels of miR-29 family members were also
significantly down-regulated in NPC tissues [19,30], as well as in
many other solid tumors. The human miR-29 family has been
shown to regulate DNA methylation through DNMT3A and 3B
[54] and to regulate cell survival through Mcl-1 and Tcl-1[55,56].
Whether BART9-3p and BART1-3p also modulate the biological
functions controlled by these human miRNAs remains to be
elucidated. Nevertheless, these results clearly suggest a complex
interplay between EBV and host miRNAs.
In the present study, we utilized the next generation sequencing
technology to characterize the expression of EBV miRNAs in
NPC tissue. The quantity of sequencing reads enabled us to
identify several novel EBV miRNAs and uncover the extensive
presence of terminal and nucleotide variants of EBV miRNAs in
NPC tissue. Several highly abundant EBV miRNAs were detected
at levels equivalent to the most abundant human miRNAs in NPC
tissue. The extensive variants, coupled with their abundance,
provide a powerful network for the virus to regulate its own
biology as well as the host response.
Supporting Information
Figure S1 Genomic localization of EBV small RNAs detected in
CT10 sample. EBV small RNAs were aligned to the reference
genome NC_007605. Locations of EBERs, BHRF1 and BART
transcripts were highlighted. Shown are reads aligned to the sense
strand of EBV genome. Segments of the EBV genome, expanding
from 137,500 to 155,000, were shown in the bottom panel. Locations
for BART cluster I, cluster II, and BART2 miRNAs were highlighted.
Found at: doi:10.1371/journal.pone.0012745.s001 (0.20 MB
PDF)
Figure S2 Secondary structure of EBV miRNAs. (A) Structure
and sequences of novel EBV BART miRNAs detected in CT10.
The stem-loop structure was based on the precursor hairpins
predicted in miRBase. In all cases, the miRNA precursors give rise
to two mature miRNAs. The mature miRNA sequences of newly
discovered EBV miRNAs were indicated in red. The mature
miRNA sequences in the opposite arm were shown in uppercase.
(B) Comparison of miRBase standard sequence with the most
abundant miRNA sequence detected in CT10. The stem- loop
structure was based on the precursor hairpins predicted in
miRBase. In all cases, the miRNA precursors give rise to two
mature miRNAs. The mature miRNA sequences deposited in
miRBase were shown in uppercase. The mature sequences of most
abundant miRNAs detected in CT10 were indicated in red.
Found at: doi:10.1371/journal.pone.0012745.s002 (0.31 MB
PDF)
Figure S3 Validation of the specificity of RT primer for
isomiRs. RNAs with sequence match to 39-end isomiR of
BART5-5p (N, N-1 and N-2 in Figure 3D) were synthesized and
used as the template for isomiR detection. 16109 copies of
synthetic RNA were reverse transcribed using the indicated RT
primer. Following the RT reaction, cDNA products were
quantified using the universal reverse primer and the BART-5p
specific forward primer. PCR products of individual reaction were
analyzed using 15% polyacrylamide gel electrophoresis. Ct value
for individual qPCR reaction was listed.
Found at: doi:10.1371/journal.pone.0012745.s003 (0.18 MB
PDF)
Table S1 Primers used for real-time PCR.
Found at: doi:10.1371/journal.pone.0012745.s004 (0.02 MB
PDF)
Table S2 Terminal isomiRs of EBV microRNAs in the T10
sample.
Found at: doi:10.1371/journal.pone.0012745.s005 (0.07 MB
PDF)
Table S3 Nucleotide variants of EBV microRNAs in the T10
sample.
Found at: doi:10.1371/journal.pone.0012745.s006 (0.59 MB
PDF)
Table S4 Major EBV miRNAs detected by SOLiD sequencing
in T10 and N10 samples.
Found at: doi:10.1371/journal.pone.0012745.s007 (0.04 MB
PDF)
Table S5 Expression levels of EBV miRNAs detected by RT-
PCR in 13 NPC tissues and c666-1 cells.
Found at: doi:10.1371/journal.pone.0012745.s008 (0.02 MB
PDF)
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